Incyte (INCY) Tops Q3 EPS by 46c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- AI stocks lift Wall St as oil falls, Treasury yields decline
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
- Novo Nordisk shares drop as investor event disappoints
Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
November 2, 2021 7:00 AM EDTTotal product and royalty revenues of $778 million in Q3 2021 (+25% vs. Q3 2020); Jakafi® (ruxolitinib) revenues of $547 million in Q3 2021 (+12% vs. Q3 2020) Three regulatory approvals including OpzeluraTM (ruxolitinib) cream in the U.S. for the treatment of atopic dermatitis, Jakafi in the U.S. for the treatment of chronic graft-versus-host disease (GVHD) and Minjuvi® (tafasitamab) in Europe for the treatment of relapsed or refractory DLBCL Pivotal TRuE-V data presentation at EADV highlighted significant improvements in facial and total body repigmentation in vitiligo patients treated with ruxolitinib cream; Company pursuing regulatory... More
